Key Points
- Insider Kevin Mcculloch sold 15,000 shares of Xeris Biopharma (NASDAQ:XERS) on Jan. 8 at an average price of $8.00 for $120,000, leaving him with 1,685,426 shares (a 0.88% reduction).
- Xeris opened at $7.93, has a market capitalization of $1.32 billion, and recently reported a quarterly EPS miss (EPS $0.00 vs. $0.01 estimate) with revenue roughly in line at $74.38 million.
- Analysts have a consensus "Moderate Buy" rating with a consensus price target of $9.50, reflecting six Buy, two Hold and one Sell ratings.
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Kevin Mcculloch sold 15,000 shares of the stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $8.00, for a total transaction of $120,000.00. Following the sale, the insider directly owned 1,685,426 shares of the company's stock, valued at $13,483,408. The trade was a 0.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Xeris Biopharma Trading Down 2.5%
NASDAQ XERS opened at $7.93 on Friday. The firm's fifty day simple moving average is $7.36 and its two-hundred day simple moving average is $7.17. The firm has a market capitalization of $1.32 billion, a P/E ratio of -79.29 and a beta of 0.50. Xeris Biopharma Holdings, Inc. has a 12-month low of $3.14 and a 12-month high of $10.08.
Xeris Biopharma (NASDAQ:XERS - Get Free Report) last posted its quarterly earnings data on Thursday, November 6th. The company reported $0.00 earnings per share for the quarter, missing analysts' consensus estimates of $0.01 by ($0.01). The firm had revenue of $74.38 million during the quarter, compared to analysts' expectations of $74.19 million. As a group, sell-side analysts predict that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several analysts have weighed in on XERS shares. Zacks Research downgraded shares of Xeris Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Thursday, October 30th. HC Wainwright reissued a "buy" rating and issued a $10.00 target price on shares of Xeris Biopharma in a research report on Friday. Wall Street Zen cut Xeris Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Saturday, November 8th. Piper Sandler boosted their price target on Xeris Biopharma from $6.00 to $8.00 and gave the company a "neutral" rating in a research note on Friday, November 7th. Finally, Barclays assumed coverage on Xeris Biopharma in a research note on Monday, December 8th. They issued an "overweight" rating and a $9.00 price objective for the company. Six investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $9.50.
Check Out Our Latest Stock Report on XERS
Hedge Funds Weigh In On Xeris Biopharma
Institutional investors and hedge funds have recently modified their holdings of the stock. Royal Bank of Canada grew its holdings in Xeris Biopharma by 1,411.2% during the first quarter. Royal Bank of Canada now owns 213,084 shares of the company's stock worth $1,170,000 after acquiring an additional 198,984 shares during the period. AQR Capital Management LLC increased its holdings in shares of Xeris Biopharma by 13.4% during the 1st quarter. AQR Capital Management LLC now owns 946,766 shares of the company's stock valued at $5,198,000 after purchasing an additional 111,826 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in shares of Xeris Biopharma in the 1st quarter valued at $1,403,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Xeris Biopharma by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company's stock valued at $461,000 after purchasing an additional 3,594 shares during the period. Finally, Millennium Management LLC boosted its holdings in Xeris Biopharma by 19.0% during the first quarter. Millennium Management LLC now owns 2,317,972 shares of the company's stock worth $12,726,000 after buying an additional 369,420 shares in the last quarter. Institutional investors and hedge funds own 42.75% of the company's stock.
Xeris Biopharma Company Profile
(
Get Free Report)
Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company's proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.
The company's flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
